Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy

Pathology and Oncology Research

Volumn 18, Issue 1, 2012, Pages 61-68

  Nikolényi, Alíz ^a   Uhercsák, Gabriella ^a   Csenki, Melinda ^a   Hamar, Sándor ^a   Csörgő, Erika ^a   Tánczos, Ervin ^a   Thurzó, László ^a   Brodowicz, Thomas ^b   Wagnerova, Maria ^c   Kahán, Zsuzsanna ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Central European Cooperative Oncology Group   (Austria)

^c Vychodoslovensky Onkologicky Ustav Kosice   (Slovakia)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; Dose dense chemotherapy; Topoisomerase II alpha

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER RELAPSE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 84855294157     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9417-4     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. D Slamon W Eiermann N Robert, et al. 2005 BCIRG 006: 2nd interim analysis phase II randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel positive early (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res Treat 94 S5 [abstr. 1]
3. L Gianni L Norton N Wolmark TM Suter G Bonadonna GN Hortobagyi 2009 Role of anthracyclines int he treatment of early breast cancer J Clin Oncol 27 4798 4808 19687331 10.1200/JCO.2008.21.4791
4. A Gennari MP Sormani P Pronzato M Puntoni M Colozza U Pfeffer P Bruzzi 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 18159072 1:CAS:528:DC%2BD1cXit1Cku7o%3D 10.1093/jnci/djm252 (Pubitemid 351767337)
5. KI Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell National Cancer Institute of Canada Clinical Trials Group 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 16707747 1:CAS:528:DC%2BD28XkslCku7s%3D 10.1056/NEJMoa054504 (Pubitemid 43736610)
6. JM Bartlett A Munro DA Cameron J Thomas R Prescott CJ Twelves 2008 Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial J Clin Oncol 26 5027 5035 18768436 1:CAS:528:DC%2BD1cXhsVGhsrrE 10.1200/JCO.2007.14. 6597
7. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 1:CAS:528: DC%2BD2MXos1Cjs7k%3D 10.1158/1078-0432.CCR-04-2421 (Pubitemid 41170290)
8. A Di Leo L Biganzoli W Claudion S Licitra M Pestrin D Larsimont 2008 Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer 44 2791 2798 18993056 10.1016/j.ejca.2008.09.014
9. TA Järvinen ET Liu 2003 HER-2/neu and topoisomerase II alpha in breast cancer Breast Cancer Res Treat 78 299 311 12755489 10.1023/A: 1023077507295 (Pubitemid 36543210)
10. RJ Isaacs SL Davies MI Sandri C Redwood NJ Wells ID Hickson 1998 Physiological regulation of eukaryotic topoisomerase II Biochim Biophys Acta 1400 121 137 9748535 1:CAS:528:DyaK1cXmtFWisro%3D (Pubitemid 28475099)
11. KV Nielsen B Ejlertsen S Moller JT Jorgensen A Knoop H Knudsen HT Mouridsen 2008 The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D Acta Oncol 47 725 734 18465341 1:CAS:528:DC%2BD1cXnsFeiur8%3D 10.1080/02841860801995396 (Pubitemid 351878451)
12. A Di Leo D Gancberg D Larsimont M Tanner T Jarvinen G Rouas S Dolci JY Leroy M Paesmans J Isola MJ Piccart 2002 HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 12006526 (Pubitemid 34517647)
13. AS Knoop H Knudsen E Balslev BB Rasmussen J Overgaard KV Nielsen A Schonau K Gunnarsdóttir KE Olsen H Mouridsen B Ejlertsen Danish Breast Cancer Cooperative Group 2005 Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group J Clin Oncol 23 7483 7490 16234514 1:CAS:528: DC%2BD2MXht1WrsrzK 10.1200/JCO.2005.11.007 (Pubitemid 46291811)
14. FP O'Malley S Chia D Tu LE Shepherd MN Levine VH Bramwell IL Andrulis KI Pritchard 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 644 650 19401546 10.1093/jnci/djp067
15. LN Harris G Broadwater M Abu-Khalaf D Cowan AD Thor D Budman CT Cirrincione DA Berry EP Winer CA Hudis DF Hayes P Friedman M Ellis L Dressler 2009 Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 J Clin Oncol 27 3430 3436 19470942 1:CAS:528:DC%2BD1MXhtVSqtLvL 10.1200/JCO.2008.18.4085
16. E Arriola SM Rodriguez-Pinilla MBK Lambros RL Jones M James K Savage IE Smith M Dowsett JS Reis-Filho 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 181 189 17260090 1:CAS:528:DC%2BD2sXht1CgtL7M 10.1007/s10549-006-9492-5 (Pubitemid 350045015)
17. C Schindlbeck D Mayr C Olivier B Rack V Engelstaedter J Jueckstock C Jenderek U Andergassen U Jeschke K Friese 2010 Topoisomerase II alpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer J Cancer Res Clin Oncol 136 1029 1037 20052594 1:CAS:528:DC%2BC3cXmtlyisL8%3D 10.1007/s00432-009-0748-4
18. M Tanner J Isola T Wiklund B Erikstein P Kellokumpu-Lehtinen P Malmström N Wilking J Nilsson J Bergh 2006 Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 2428 2436 16682728 1:CAS:528:DC%2BD28XmtVOmsLc%3D 10.1200/JCO.2005.02.9264 (Pubitemid 46630618)
19. P Fritz CM Cabrera J Dippon A Gerteis W Simon WE Aulitzky H van der Kuip 2005 c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study Breast Cancer Res 7 R374 R384 15987433 1:CAS:528:DC%2BD2MXkt1equrg%3D 10.1186/bcr1012
20. V Durbecq C Desmed M Paesmans F Cardoso A Di Leo M Mano G Rouas JY Leroy C Sotiriou M Piccart D Larsimont 2004 Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer Int J Oncol 25 1473 1479 15492841 1:CAS:528:DC%2BD2cXhtVSktbbP
21. RE Mueller RK Parkes I Andrulis FP O'Malley 2004 Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples Genes Chromosomes Cancer 39 288 297 14978790 1:CAS:528:DC%2BD2cXivFKjsbw%3D 10.1002/gcc.20008 (Pubitemid 38326310)
22. G Callagy P Pharoah SF Chin T Sangan Y Daigo L Jackson C Caldas 2005 Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays J Pathol 205 388 396 15682439 1:CAS:528:DC%2BD2MXit1Orurs%3D 10.1002/path.1694 (Pubitemid 40253928)
23. JC Brase M Schmidt T Fischbach H Sültmann H Bojar H Koelbl B Hellwig J Rahnenführer JG Hengstler MC Gehrmann 2010 ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction Clin Cancer Res 16 2391 2401 20371687 1:CAS:528:DC%2BC3cXkslSls70%3D 10.1158/1078-0432.CCR-09-2471
24. GE Konecny G Pauletti M Untch HJ Wang V Möbus W Kuhn C Thomssen N Harbeck L Wang S Apple F Jänicke DJ Slamon 2010 Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer Breast Cancer Res Treat 120 481 489 20130985 1:CAS:528:DC%2BC3cXjtlahur8%3D 10.1007/s10549-010-0744-z
25. V Durbecq M Paesmans F Cardoso C Desmedt A Di Leo S Chan K Friedrichs T Pinter S Van Belle E Murray I Bodrogi E Walpole B Lesperance S Korec J Crown P Simmonds TJ Perren JY Leroy G Rouas C Sotiriou M Piccart D Larsimont 2004 Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol Cancer Ther 3 1207 1214 15486187 1:CAS:528:DC%2BD2cXosVSrs74%3D (Pubitemid 39440165)
26. Z Kahan G Uhercsak R Hajnal-Papp K Boda L Thurzo 2005 Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer Oncology 68 446 453 16020975 1:CAS:528:DC%2BD2MXnvFyms7Y%3D 10.1159/000086987 (Pubitemid 41160976)
27. Z Kahán S Spanik M Wagnerova T Skacel B Planko E Fitzthum E Lindner V Soldatenkova CC Zielinski T Brodowicz 2008 Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG) Breast Cancer Res Treat 112 557 563 18189160 10.1007/s10549-008-9894-7
28. A Nocito J Kononen OP Kallioniemi G Sauter 2001 Tissue microarrays (TMAs) for high-throughput molecular pathology research Int J Cancer 94 1 5 11668471 1:CAS:528:DC%2BD3MXms1Kgs7k%3D 10.1002/ijc.1385 (Pubitemid 32801745)
29. K Park J Kim S Lim S Han 2003 Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy Eur J Cancer 395 631 634 10.1016/S0959-8049(02)00745-1 (Pubitemid 36287375)
30. R Tubbs WE Barlow GT Budd E Swain P Porter A Gown IT Yeh G Sledge C Shapiro J Ingle C Haskell KS Albain R Livingston DF Hayes 2009 Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status J Clin Oncol 27 3881 3886 19620488 1:CAS:528:DC%2BD1MXhtFCgsb3P 10.1200/JCO.2008.20.1566
31. KA Gunnarsdóttir MB Jensen D Zahrieh RD Gelber A Knoop M Bonetti H Mouridsen B Ejlertsen 2010 CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D Breast Cancer Res Treat 123 163 169 20464479 10.1007/s10549-010-0931-y
32. J Hannemann P Kristel H van Tinteren M Bontenbal QG van Hoesel WM Smit MA Nooij EE Voest E van der Wall P Hupperets EG de Vries S Rodenhuis MJ van de Vijver 2006 Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy Br J Cancer 95 1334 1341 17088909 1:CAS:528:DC%2BD28XhtF2ns7%2FE 10.1038/sj.bjc.6603449 (Pubitemid 44760082)
33. A Di Leo D Larsimont D Gancberg T Jarvinen M Beauduin A Vindevoghel J Michel CH Focan F Ries PH Gobert MT Closon-Dejardin S Dolci G Rouas M Paesmans JP Lobelle J Isola MJ Piccart 2001 HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 1081 1089 11583189 10.1023/A:1011669223035 (Pubitemid 32834488)
34. DA Berry C Cirrincione IC Henderson ML Citron DR Budman LJ Goldstein S Martino EA Perez HB Muss L Norton C Hudis EP Winer 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA. 295 1658 1667 16609087 1:CAS:528:DC%2BD28XjsVeqs7k%3D 10.1001/jama.295.14.1658
35. A Rody T Karn E Ruckhäberle V Müller M Gehrmann C Solbach A Ahr R Gätje U Holtrich M Kaufmann 2009 Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer Breast Cancer Res Treat 113 4574 66 10.1007/s10549-008-9964-x
36. TA Järvinen J Kononen M Pelto-Huikko J Isola 1996 Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer Am J Pathol 148 2073 2082 8669491 (Pubitemid 26170530)